Literature DB >> 19338025

Neurochemical changes in the rat prefrontal cortex following acute phencyclidine treatment: an in vivo localized (1)H MRS study.

Isabelle Iltis1, Dee M Koski, Lynn E Eberly, Christopher D Nelson, Dinesh K Deelchand, Julien Valette, Kamil Ugurbil, Kelvin O Lim, Pierre-Gilles Henry.   

Abstract

Acute phencyclidine (PCP) administration mimics some aspects of schizophrenia in rats, such as behavioral alterations, increased dopaminergic activity and prefrontal cortex dysfunction. In this study, we used single-voxel (1)H-MRS to investigate neurochemical changes in rat prefrontal cortex in vivo before and after an acute injection of PCP. A short-echo time sequence (STEAM) was used to acquire spectra in a 32-microL voxel positioned in the prefrontal cortex area of 12 rats anesthetized with isoflurane. Data were acquired for 30 min before and for 140 min after a bolus of PCP (10 mg/kg, n = 6) or saline (n = 6). Metabolites were quantified with the LCModel. Time courses for 14 metabolites were obtained with a temporal resolution of 10 min. The glutamine/glutamate ratio was significantly increased after PCP injection (p < 0.0001, pre- vs. post-injection), while the total concentration of these two metabolites remained constant. Glucose was transiently increased (+70%) while lactate decreased after the injection (both p < 0.0001). Lactate, but not glucose and glutamine, returned to baseline levels after 140 min. These results show that an acute injection of PCP leads to changes in glutamate and glutamine concentrations, similar to what has been observed in schizophrenic patients, and after ketamine administration in humans. MRS studies of this pharmacological rat model may be useful for assessing the effects of potential anti-psychotic drugs in vivo. 2009 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19338025      PMCID: PMC2732191          DOI: 10.1002/nbm.1385

Source DB:  PubMed          Journal:  NMR Biomed        ISSN: 0952-3480            Impact factor:   4.044


  51 in total

Review 1.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

2.  Glial-neuronal interactions are impaired in the schizophrenia model of repeated MK801 exposure.

Authors:  Daniel Kondziella; Eiliv Brenner; Elvar M Eyjolfsson; Katarina Ryden Markinhuhta; Maria L Carlsson; Ursula Sonnewald
Journal:  Neuropsychopharmacology       Date:  2005-12-14       Impact factor: 7.853

3.  Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice.

Authors:  S Miyamoto; J N Leipzig; J A Lieberman; G E Duncan
Journal:  Neuropsychopharmacology       Date:  2000-04       Impact factor: 7.853

4.  First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients.

Authors:  L S Pilowsky; R A Bressan; J M Stone; K Erlandsson; R S Mulligan; J H Krystal; P J Ell
Journal:  Mol Psychiatry       Date:  2006-02       Impact factor: 15.992

5.  Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats.

Authors:  B Moghaddam; B W Adams
Journal:  Science       Date:  1998-08-28       Impact factor: 47.728

6.  Mitochondrial activity in the mapping of functional brain changes in schizophrenia.

Authors:  J A Prince; L Oreland
Journal:  Restor Neurol Neurosci       Date:  1998-06       Impact factor: 2.406

7.  Neurochemical changes in Huntington R6/2 mouse striatum detected by in vivo 1H NMR spectroscopy.

Authors:  Ivan Tkac; Janet M Dubinsky; C Dirk Keene; Rolf Gruetter; Walter C Low
Journal:  J Neurochem       Date:  2007-01-08       Impact factor: 5.372

8.  Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex.

Authors:  B Moghaddam; B Adams; A Verma; D Daly
Journal:  J Neurosci       Date:  1997-04-15       Impact factor: 6.167

9.  Role of the simultaneous enhancement of NMDA and dopamine D1 receptor-mediated neurotransmission in the effects of clozapine on phencyclidine-induced acute increases in glutamate levels in the rat medial prefrontal cortex.

Authors:  T Abekawa; K Ito; T Koyama
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-11-14       Impact factor: 3.000

10.  Regional cerebral blood flow and negative/positive symptoms in 24 drug-naive schizophrenics.

Authors:  O Sabri; R Erkwoh; M Schreckenberger; U Cremerius; G Schulz; C Dickmann; H J Kaiser; E M Steinmeyer; H Sass; U Buell
Journal:  J Nucl Med       Date:  1997-02       Impact factor: 10.057

View more
  36 in total

1.  ¹H-[¹³C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism.

Authors:  Golam M I Chowdhury; Kevin L Behar; William Cho; Monique A Thomas; Douglas L Rothman; Gerard Sanacora
Journal:  Biol Psychiatry       Date:  2011-12-09       Impact factor: 13.382

2.  Glutamate carboxypeptidase II and folate deficiencies result in reciprocal protection against cognitive and social deficits in mice: implications for neurodevelopmental disorders.

Authors:  Laura R Schaevitz; Jonathan D Picker; Jasmine Rana; Nancy H Kolodny; Barry Shane; Joanne E Berger-Sweeney; Joseph T Coyle
Journal:  Dev Neurobiol       Date:  2012-06       Impact factor: 3.964

3.  Cortical metabolites as biomarkers in the R6/2 model of Huntington's disease.

Authors:  Lori Zacharoff; Ivan Tkac; Qingfeng Song; Chuanning Tang; Patrick J Bolan; Silvia Mangia; Pierre-Gilles Henry; Tongbin Li; Janet M Dubinsky
Journal:  J Cereb Blood Flow Metab       Date:  2011-11-02       Impact factor: 6.200

Review 4.  Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders.

Authors:  Cagri Yüksel; Dost Öngür
Journal:  Biol Psychiatry       Date:  2010-08-21       Impact factor: 13.382

Review 5.  Glutamate-mediated excitotoxicity in schizophrenia: a review.

Authors:  Eric Plitman; Shinichiro Nakajima; Camilo de la Fuente-Sandoval; Philip Gerretsen; M Mallar Chakravarty; Jane Kobylianskii; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Eur Neuropsychopharmacol       Date:  2014-08-01       Impact factor: 4.600

6.  An Examination of Rostral Anterior Cingulate Cortex Function and Neurochemistry in Obsessive-Compulsive Disorder.

Authors:  Brian P Brennan; Olga Tkachenko; Zachary J Schwab; Richard J Juelich; Erin M Ryan; Alison J Athey; Harrison G Pope; Michael A Jenike; Justin T Baker; William D S Killgore; James I Hudson; J Eric Jensen; Scott L Rauch
Journal:  Neuropsychopharmacology       Date:  2015-02-09       Impact factor: 7.853

7.  Increased glutamine in patients undergoing long-term treatment for schizophrenia: a proton magnetic resonance spectroscopy study at 3 T.

Authors:  Juan R Bustillo; Hongji Chen; Thomas Jones; Nicholas Lemke; Christopher Abbott; Clifford Qualls; Jose Canive; Charles Gasparovic
Journal:  JAMA Psychiatry       Date:  2014-03       Impact factor: 21.596

8.  Relationship among Glutamine, γ-Aminobutyric Acid, and Social Cognition in Autism Spectrum Disorders.

Authors:  David M Cochran; Elif M Sikoglu; Steven M Hodge; Richard A E Edden; Ann Foley; David N Kennedy; Constance M Moore; Jean A Frazier
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-04-28       Impact factor: 2.576

9.  Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole.

Authors:  Brian P Brennan; James I Hudson; J Eric Jensen; Julie McCarthy; Jacqueline L Roberts; Andrew P Prescot; Bruce M Cohen; Harrison G Pope; Perry F Renshaw; Dost Ongür
Journal:  Neuropsychopharmacology       Date:  2009-12-02       Impact factor: 7.853

10.  Altered Glutamate and Regional Cerebral Blood Flow Levels in Schizophrenia: A 1H-MRS and pCASL study.

Authors:  S Andrea Wijtenburg; Susan N Wright; Stephanie A Korenic; Frank E Gaston; Nkemdilim Ndubuizu; Joshua Chiappelli; Robert P McMahon; Hongji Chen; Anya Savransky; Xiaoming Du; Danny J J Wang; Peter Kochunov; L Elliot Hong; Laura M Rowland
Journal:  Neuropsychopharmacology       Date:  2016-08-26       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.